RT Journal Article SR Electronic T1 Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 1718 DO 10.1183/13993003.congress-2020.1718 VO 56 IS suppl 64 A1 Berzenji, Lawek A1 Michaux, Dario A1 Yogeswaran, Suresh Krishan A1 Van Breussegem, Annemie A1 Lauwers, Patrick A1 Raskin, Jo A1 Hendriks, Jeroen A1 Van Meerbeeck, Jan A1 Van Schil, Paul YR 2020 UL https://publications.ersnet.org//content/56/suppl_64/1718.abstract AB Objective: The role and timing of surgery for malignant pleural mesothelioma (MPM) in a multimodal setting remains a controversial topic. Earlier studies suggest that pleurectomy/decortication (P/D) achieves similar or better oncological results and overall survival rates compared to extrapleural pneumonectomy. The aim of this study is to investigate outcomes in patients undergoing P/D for MPM at a single centre.Methods: Clinical and pathological characteristics of MPM patients treated by P/D between January 2013 and January 2020 were reviewed. Overall 30- and 90-day mortality and 1- and 2-year survival rates were calculated. Univariate and regression analyses of factors related to long-term survival were performed. Kaplan-Meier curves and the long-rank test were used to analyse differences between induction and adjuvant chemotherapy.Results: A total of 41 patients (31 male and 9 female) with a mean age of 65±7.8 years underwent P/D for MPM. The 30- and 90-day mortality rates were 2.5% and 5.4%, respectively. Overall 1-, and 2-year survival (OS) rates were 67.6% and 41.4%, respectively. Progressive disease occurred in 63.2% of all patients. Multiple regression analysis revealed age>70 years, asbestos exposure, T-status, N-status, tumour pathology, (neo)adjuvant therapy, postoperative morbidity, and progressive disease as significant prognostic factors (p<0.05). Prognosis was significantly better in the induction chemotherapy group compared to the adjuvant chemotherapy group (p=0.03).Conclusion: Patients treated with P/D for MPM in a multimodal setting have acceptable overall survival rates. The findings suggest that induction chemotherapy results in better OS than adjuvant chemotherapy.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1718.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).